非ST段抬高型急性冠脉综合征患者侵入性策略最佳时机的随机试验荟萃分析
该荟萃分析纳入8项随机对照试验共5324例非ST段抬高型急性冠脉综合征患者,比较早期与延迟侵入性策略对死亡率的影响,中位随访180天。总体早期侵入性策略未显著降低死亡率(HR 0.81,95%CI 0.64-1.03;p=0.0879),但在基线心肌标志物升高、糖尿病、GRACE风险评分>140及年龄≥75岁的高危患者中,早期策略与死亡率降低相关。
要点
- 总体早期侵入性策略未显著降低非ST段抬高型急性冠脉综合征患者死亡率(HR 0.81,95%CI 0.64-1.03;p=0.0879)。
- 基线心肌标志物升高患者中,早期策略与死亡率降低相关(HR 0.761,95%CI 0.581-0.996)。
- 糖尿病、GRACE评分>140及年龄≥75岁患者中,早期策略亦与死亡率降低相关,但交互作用检验未得出结论。
核心结论
- 对于所有非ST段抬高型急性冠脉综合征患者,早期侵入性策略与延迟侵入性策略相比未降低死亡率。
- 但在高危患者中,早期侵入性策略可能降低死亡率。
研究设计与样本
- 研究类型为荟萃分析,检索MEDLINE、Cochrane中央对照试验注册库和Embase,纳入比较早期与延迟侵入性策略的随机对照试验。
- 纳入标准为报告院内随机化后至少30天全因死亡率且试验研究者同意合作提供个体患者数据或标准化表格数据的试验。
- 共纳入8项试验,5324例患者,中位随访180天(IQR 180-360)。
- 采用随机效应模型合并风险比(HR),该荟萃分析在PROSPERO注册(CRD42015018988)。
主要发现
- 总体早期侵入性组与延迟侵入性组相比,死亡率无显著降低(HR 0.81,95%CI 0.64-1.03;p=0.0879)。
- 基线心肌标志物升高患者中,早期侵入性策略与较低死亡率相关(HR 0.761,95%CI 0.581-0.996)。
- 糖尿病患者中,早期侵入性策略与较低死亡率相关(HR 0.67,95%CI 0.45-0.99)。
- GRACE风险评分>140患者中,早期侵入性策略与较低死亡率相关(HR 0.70,95%CI 0.52-0.95)。
- 年龄≥75岁患者中,早期侵入性策略与较低死亡率相关(HR 0.65,95%CI 0.46-0.93),但交互作用检验未得出结论。
关键数值与推荐
- 总体人群:早期侵入性组 vs 延迟侵入性组,HR 0.81(95%CI 0.64-1.03;p=0.0879),未达统计学显著。
- 基线心肌标志物升高患者:早期侵入性组 vs 延迟侵入性组,HR 0.761(95%CI 0.581-0.996)。
- 糖尿病患者:早期侵入性组 vs 延迟侵入性组,HR 0.67(95%CI 0.45-0.99)。
- GRACE风险评分>140患者:早期侵入性组 vs 延迟侵入性组,HR 0.70(95%CI 0.52-0.95)。
- 年龄≥75岁患者:早期侵入性组 vs 延迟侵入性组,HR 0.65(95%CI 0.46-0.93)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A routine invasive strategy is recommended for patients with non-ST-elevation acute coronary syndromes (NSTE-ACS). However, optimal timing of invasive strategy is less clearly defined. Individual clinical trials were underpowered to detect a mortality benefit; we therefore did a meta-analysis to assess the effect of timing on mortality. METHODS: We identified randomised controlled trials comparing an early versus a delayed invasive strategy in patients presenting with NSTE-ACS by searching MEDLINE, Cochrane Central Register of Controlled Trials, and Embase. We included trials that reported all-cause mortality at least 30 days after in-hospital randomisation and for which the trial investigators agreed to collaborate (ie, providing individual patient data or standardised tabulated data). We pooled hazard ratios (HRs) using random-effects models. This meta-analysis is registered at PROSPERO (CRD42015018988). FINDINGS: We included eight trials (n=5324 patients) with a median follow-up of 180 days (IQR 180-360). Overall, there was no significant mortality reduction in the early invasive group compared with the delayed invasive group HR 0·81, 95% CI 0·64-1·03; p=0·0879). In pre-specified analyses of high-risk patients, we found lower mortality with an early invasive strategy in patients with elevated cardiac biomarkers at baseline (HR 0·761, 95% CI 0·581-0·996), diabetes (0·67, 0·45-0·99), a GRACE risk score more than 140 (0·70, 0·52-0·95), and aged 75 years older (0·65, 0·46-0·93), although tests for interaction were inconclusive. INTERPRETATION: An early invasive strategy does not reduce mortality compared with a delayed invasive strategy in all patients with NSTE-ACS. However, an early invasive strategy might reduce mortality in high-risk patients. FUNDING: None.
引用
- Jobs A, Mehta SR, Montalescot G, et al. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. Lancet. 2017. PMID: 28778541. doi:10.1016/S0140-6736(17)31490-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。